基于短链脂肪酸防治代谢性疾病的研究进展

doi:10.12114/j.issn.1007-9572.2021.02.135

摘要/Abstract

摘要： 短链脂肪酸（SCFAs）是一类含有1~6个碳原子的饱和脂肪酸，主要由肠道内特定菌群通过发酵膳食纤维产生，对维持肠道内环境稳态发挥重要作用。近年来研究表明SCFAs可调节糖脂代谢、调节能量平衡、维持肠道屏障、减轻炎性反应，并通过上述多途径参与2型糖尿病、肥胖、脂代谢紊乱、非酒精性脂肪性肝病等代谢性疾病的发生与发展。本文总结了SCFAs调控代谢的机制及其防治代谢性疾病的研究进展，旨在为代谢性疾病的防治提供更多参考资料。

关键词: 脂肪酸类, 短链脂肪酸, 代谢疾病, 胃肠道微生物组, 综述

Abstract:

Short chain fatty acids (SCFAs) are a class of saturated fatty acids containing 1-6 carbon atoms, which are mainly produced by specific flora in the intestine through the fermentation of dietary fiber, and play an important role in maintaining the homeostasis of the intestinal environment. Recent studies have shown that SCFAs can regulate glucose and lipid metabolism, regulate energy balance, maintain the intestinal barrier and reduce inflammatory responses, eventually participating in the occurrence and development of metabolic diseases such as type 2 diabetes mellitus, obesity, lipid metabolic disorders and nonalcoholic fat liver disease through the above multiple pathways. This article summarizes the mechanism of SCFAs regulating metabolism and the research progress in the prevention and treatment of metabolic diseases, in order to provide more reference materials for the prevention and treatment of metabolic diseases.

Key words: Fatty acids, Short chain fatty acids, Metabolic diseases, Gastrointestinal microbiome, Review

中图分类号:

R344.7

曾霖,张鹏翔,黄倩,等. 基于短链脂肪酸防治代谢性疾病的研究进展[J]. 中国全科医学, 2022, 25(09): 1141-1147. DOI: 10.12114/j.issn.1007-9572.2021.02.135.

ZENG Lin, ZHANG Pengxiang, HUANG Qian, WANG Gaoxiang, LI Huilin.

Research Progress of the Prevention and Treatment of Metabolic Diseases Based on Short Chain Fatty Acids [J]. Chinese General Practice, 2022, 25(09): 1141-1147.

参考文献 79

[1]	KIMURA I，ICHIMURA A，OHUE-KITANO R，et al. Free fatty acid receptors in health and disease[J]. Physiol Rev，2020，100(1):171-210. DOI：10.1152/physrev.00041.2018.
[2]	KOH A，DE VADDER F，KOVATCHEVA-DATCHARY P，et al. From dietary fiber to host physiology：short-chain fatty acids as key bacterial metabolites[J]. Cell，2016，165(6):1332-1345. DOI：10.1016/j.cell.2016.05.041.
[3]	STUMPFF F. A look at the smelly side of physiology：transport of short chain fatty acids[J]. Pflugers Arch，2018，470(4):571-598. DOI：10.1007/s00424-017-2105-9.
[4]	SIVAPRAKASAM S，BHUTIA Y D，YANG S，et al. Short-chain fatty acid transporters：role in colonic homeostasis[J]. Compr Physiol，2017，8(1):299-314. DOI：10.1002/cphy.c170014.
[5]	PSICHAS A，SLEETH M L，MURPHY K G，et al. The short chain fatty acid propionate stimulates GLP-1 and PYY secretion via free fatty acid receptor 2 in rodents[J]. Int J Obes：Lond，2015，39(3):424-429. DOI：10.1038/ijo.2014.153.
[6]	NARAOKA Y，YAMAGUCHI T，HU A，et al. Short chain fatty acids upregulate adipokine production in type 2 diabetes-derived human adipocytes[J]. Acta Endocrinol （Buchar），2018，14(3):287-293. DOI：10.4183/aeb.2018.287.
[7]	LI Z，YI C X，KATIRAEI S，et al. Butyrate reduces appetite and activates brown adipose tissue via the gut-brain neural circuit[J]. Gut，2018，67(7):1269-1279. DOI：10.1136/gutjnl-2017-314050.
[8]	FROST G，SLEETH M L，SAHURI-ARISOYLU M，et al. The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism[J]. Nat Commun，2014，5:3611. DOI：10.1038/ncomms4611.
[9]	PERRY R J，PENG L，BARRY N A，et al. Acetate mediates a microbiome-brain-β-cell axis to promote metabolic syndrome[J]. Nature，2016，534(7606):213-217. DOI：10.1038/nature18309.
[10]	KIMURA I，OZAWA K，INOUE D，et al. The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43[J]. Nat Commun，2013，4:1829. DOI：10.1038/ncomms2852.
[11]	LU Y Y，FAN C N，LI P，et al. Short chain fatty acids prevent high-fat-diet-induced obesity in mice by regulating G protein-coupled receptors and gut microbiota[J]. Sci Rep，2016，6:37589. DOI：10.1038/srep37589.
[12]	SAMBEAT A，GULYAEVA O，DEMPERSMIER J，et al. LSD1 interacts with Zfp516 to promote UCP1 transcription and brown fat program[J]. Cell Rep，2016，15(11):2536-2549. DOI：10.1016/j.celrep.2016.05.019.
[13]	WANG D，LIU C D，LI H F，et al. LSD1 mediates microbial metabolite butyrate-induced thermogenesis in brown and white adipose tissue[J]. Metabolism，2020，102:154011. DOI：10.1016/j.metabol.2019.154011.
[14]	BO T B，ZHANG X Y，WEN J，et al. The microbiota-gut-brain interaction in regulating host metabolic adaptation to cold in male Brandt's voles （Lasiopodomys brandtii）[J]. Isme J，2019，13(12):3037-3053. DOI：10.1038/s41396-019-0492-y.
[15]	KHAKISAHNEH S，ZHANG X Y，NOURI Z，et al. Gut microbiota and host thermoregulation in response to ambient temperature fluctuations[J]. mSystems，2020，5(5):e514-520. DOI：10.1128/mSystems.00514-20.
[16]	DE GOFFAU M C，LUOPAJÄRVI K，KNIP M，et al. Fecal microbiota composition differs between children with β-cell autoimmunity and those without[J]. Diabetes，2013，62(4):1238-1244. DOI：10.2337/db12-0526.
[17]	LI H P，CHEN X，LI M Q. Butyrate alleviates metabolic impairments and protects pancreatic β cell function in pregnant mice with obesity[J]. Int J Clin Exp Pathol，2013，6(8):1574-1584.
[18]	LUNDH M，GALBO T，POULSEN S S，et al. Histone deacetylase 3 inhibition improves glycaemia and insulin secretion in obese diabetic rats[J]. Diabetes Obes Metab，2015，17(7):703-707. DOI：10.1111/dom.12470.
[19]	YAMATO E. High dose of histone deacetylase inhibitors affects insulin secretory mechanism of pancreatic beta cell line[J]. Endocr Regul，2018，52(1):21-26. DOI：10.2478/enr-2018-0004.
[20]	KHAN S，JENA G B. Protective role of sodium butyrate，a HDAC inhibitor on beta-cell proliferation，function and glucose homeostasis through modulation of p38/ERK MAPK and apoptotic pathways：study in juvenile diabetic rat[J]. Chem Biol Interact，2014，213:1-12. DOI：10.1016/j.cbi.2014.02.001.
[21]	ELGAMAL D A，ABOU-ELGHAIT A T，ALI A Y，et al. Ultrastructure characterization of pancreatic β-cells is accompanied by modulatory effects of the HDAC inhibitor sodium butyrate on the PI3/AKT insulin signaling pathway in juvenile diabetic rats[J]. Mol Cell Endocrinol，2020，503:110700. DOI：10.1016/j.mce.2019.110700.
[22]	GUO Y，XIAO Z，WANG Y N，et al. Sodium butyrate ameliorates streptozotocin-induced type 1 diabetes in mice by inhibiting the HMGB1 expression[J]. Front Endocrinol （Lausanne），2018，9:630. DOI：10.3389/fendo.2018.00630.
[23]	DEN BESTEN G，BLEEKER A，GERDING A，et al. Short-chain fatty acids protect against high-fat diet-induced obesity via a PPARγ-dependent switch from lipogenesis to fat oxidation[J]. Diabetes，2015，64(7):2398-2408. DOI：10.2337/db14-1213.
[24]	MOLLICA M P，MATTACE RASO G，CAVALIERE G，et al. Butyrate regulates liver mitochondrial function，efficiency，and dynamics in insulin-resistant obese mice[J]. Diabetes，2017，66(5):1405-1418. DOI：10.2337/db16-0924.
[25]	TIROSH A，CALAY E S，TUNCMAN G，et al. The short-chain fatty acid propionate increases glucagon and FABP4 production，impairing insulin action in mice and humans[J]. Sci Transl Med，2019，11(489):eaav0120. DOI：10.1126/scitranslmed.aav0120.
[26]	DE VADDER F，KOVATCHEVA-DATCHARY P，ZITOUN C，et al. Microbiota-produced succinate improves glucose homeostasis via intestinal gluconeogenesis[J]. Cell Metab，2016，24(1):151-157. DOI：10.1016/j.cmet.2016.06.013.
[27]	DE VADDER F，KOVATCHEVA-DATCHARY P，GONCALVES D，et al. Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits[J]. Cell，2014，156(1/2):84-96. DOI：10.1016/j.cell.2013.12.016.
[28]	LU Y Y，FAN C N，LI P，et al. Short chain fatty acids prevent high-fat-diet-induced obesity in mice by regulating G protein-coupled receptors and gut microbiota[J]. Sci Rep，2016，6:37589. DOI：10.1038/srep37589.
[29]	LI Z，YI C X，KATIRAEI S，et al. Butyrate reduces appetite and activates brown adipose tissue via the gut-brain neural circuit[J]. Gut，2018，67(7):1269-1279. DOI：10.1136/gutjnl-2017-314050.
[30]	VOZZA A，PARISI G，DE LEONARDIS F，et al. UCP2 transports C4 metabolites out of mitochondria，regulating glucose and glutamine oxidation[J]. Proc Natl Acad Sci USA，2014，111(3):960-965. DOI：10.1073/pnas.1317400111.
[31]	GAO Z G，YIN J，ZHANG J，et al. Butyrate improves insulin sensitivity and increases energy expenditure in mice[J]. Diabetes，2009，58(7):1509-1517. DOI：10.2337/db08-1637.
[32]	HENAGAN T M，STEFANSKA B，FANG Z D，et al. Sodium butyrate epigenetically modulates high-fat diet-induced skeletal muscle mitochondrial adaptation，obesity and insulin resistance through nucleosome positioning[J]. Br J Pharmacol，2015，172(11):2782-2798. DOI：10.1111/bph.13058.
[33]	ARAÚJO J R，TAZI A，BURLEN-DEFRANOUX O，et al. Fermentation products of commensal bacteria alter enterocyte lipid metabolism[J]. Cell Host Microbe，2020，27(3):358-375.e7. DOI：10.1016/j.chom.2020.01.028.
[34]	GUI H B，SHEN Z M. Concentrate diet modulation of ruminal genes involved in cell proliferation and apoptosis is related to combined effects of short-chain fatty acid and pH in rumen of goats[J]. J Dairy Sci，2016，99(8):6627-6638. DOI：10.3168/jds.2015-10446.
[35]	ZHAO J B，LIU P，WU Y，et al. Dietary fiber increases butyrate-producing bacteria and improves the growth performance of weaned piglets[J]. J Agric Food Chem，2018，66(30):7995-8004. DOI：10.1021/acs.jafc.8b02545.
[36]	FENG Y H，WANG Y，WANG P，et al. Short-chain fatty acids manifest stimulative and protective effects on intestinal barrier function through the inhibition of NLRP3 inflammasome and autophagy[J]. Cell Physiol Biochem，2018，49(1):190-205. DOI：10.1159/000492853.
[37]	FACHI J L，SÉCCA C，RODRIGUES P B，et al. Acetate coordinates neutrophil and ILC3 responses against C. difficile through FFAR2[J]. J Exp Med，2020，217(3):e20190489. DOI：10.1084/jem.20190489.
[38]	DUSCHA A，GISEVIUS B，HIRSCHBERG S，et al. Propionic acid shapes the multiple sclerosis disease course by an immunomodulatory mechanism[J]. Cell，2020，180(6):1067-1080.e16. DOI：10.1016/j.cell.2020.02.035.
[39]	RAU M，REHMAN A，DITTRICH M，et al. Fecal SCFAs and SCFA-producing bacteria in gut microbiome of human NAFLD as a putative link to systemic T-cell activation and advanced disease[J]. United European Gastroenterol J，2018，6(10):1496-1507. DOI：10.1177/2050640618804444.
[40]	KELLY C J，ZHENG L，CAMPBELL E L，et al. Crosstalk between microbiota-derived short-chain fatty acids and intestinal epithelial HIF augments tissue barrier function[J]. Cell Host Microbe，2015，17(5):662-671. DOI：10.1016/j.chom.2015.03.005.
[41]	FORSLUND K，HILDEBRAND F，NIELSEN T，et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota[J]. Nature，2015，528(7581):262-266. DOI：10.1038/nature15766.
[42]	WU H，ESTEVE E，TREMAROLI V，et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes，contributing to the therapeutic effects of the drug[J]. Nat Med，2017，23(7):850-858. DOI：10.1038/nm.4345.
[43]	DE LA CUESTA-ZULUAGA J，MUELLER N T，CORRALES-AGUDELO V，et al. Metformin is associated with higher relative abundance of mucin-degrading Akkermansia muciniphila and several short-chain fatty acid-producing microbiota in the gut[J]. Diabetes Care，2017，40(1):54-62. DOI：10.2337/dc16-1324.
[44]	BRUNKWALL L，ORHO-MELANDER M. The gut microbiome as a target for prevention and treatment of hyperglycaemia in type 2 diabetes：from current human evidence to future possibilities[J]. Diabetologia，2017，60(6):943-951. DOI：10.1007/s00125-017-4278-3.
[45]	ZHANG X，FANG Z，ZHANG C，et al. Effects of acarbose on the gut microbiota of prediabetic patients：a randomized，double-blind，controlled crossover trial[J]. Diabetes Ther，2017，8(2):293-307. DOI：10.1007/s13300-017-0226-y.
[46]	YAN X F，FENG B，LI P C，et al. Microflora disturbance during progression of glucose intolerance and effect of sitagliptin：an animal study[J]. J Diabetes Res，2016，2016:2093171. DOI：10.1155/2016/2093171.
[47]	WANG L，LI P，TANG Z，et al. Structural modulation of the gut microbiota and the relationship with body weight：compared evaluation of liraglutide and saxagliptin treatment[J]. Sci Rep，2016，6:33251. DOI：10.1038/srep33251.
[48]	LIAO X Y，SONG L Y，ZENG B H，et al. Alteration of gut microbiota induced by DPP-4i treatment improves glucose homeostasis[J]. EBioMedicine，2019，44:665-674. DOI：10.1016/j.ebiom.2019.03.057.
[49]	JAYACHANDRAN M，CHEN J L，CHUNG S S M，et al. A critical review on the impacts of β-glucans on gut microbiota and human health[J]. J Nutr Biochem，2018，61:101-110. DOI：10.1016/j.jnutbio.2018.06.010.
[50]	ZHANG C，MA S，WU J，et al. A specific gut microbiota and metabolomic profiles shifts related to antidiabetic action：The similar and complementary antidiabetic properties of type 3 resistant starch from Canna edulis and metformin[J]. Pharmacol Res，2020，159:104985. DOI：10.1016/j.phrs.2020.104985.
[51]	LIU G，LIANG L，YU G，et al. Pumpkin polysaccharide modifies the gut microbiota during alleviation of type 2 diabetes in rats[J]. Int J Biol Macromol，2018，115:711-717. DOI：10.1016/j.ijbiomac.2018.04.127.
[52]	NIE Q，CHEN H，HU J，et al. Arabinoxylan attenuates type 2 diabetes by improvement of carbohydrate，lipid，and amino acid metabolism[J]. Mol Nutr Food Res，2018，62(20):e1800222. DOI：10.1002/mnfr.201800222.
[53]	ZHAO C，YANG C F，LIU B，et al. Bioactive compounds from marine macroalgae and their hypoglycemic benefits[J]. Trends Food Sci Technol，2018，72:1-12. DOI：10.1016/j.tifs.2017.12.001.
[54]	LIU Y Y，WANG C R，LI J S，et al. Phellinus linteus polysaccharide extract improves insulin resistance by regulating gut microbiota composition[J]. FASEB J，2020，34(1):1065-1078. DOI：10.1096/fj.201901943RR.
[55]	LIU Y M，LIU W，LI J，et al. A polysaccharide extracted from Astragalus membranaceus residue improves cognitive dysfunction by altering gut microbiota in diabetic mice[J]. Carbohydr Polym，2019，205:500-512. DOI：10.1016/j.carbpol.2018.10.041.
[56]	YAO Y，YAN L，CHEN H，et al. Cyclocarya paliurus polysaccharides alleviate type 2 diabetic symptoms by modulating gut microbiota and short-chain fatty acids[J]. Phytomedicine，2020，77:153268. DOI：10.1016/j.phymed.2020.153268.
[57]	GU W，WANG Y，ZENG L，et al. Polysaccharides from Polygonatum kingianum improve glucose and lipid metabolism in rats fed a high fat diet[J]. Biomed Pharmacother，2020，125:109910. DOI：10.1016/j.biopha.2020.109910.
[58]	ZHU K X，FAN H F，ZENG S J，et al. Polysaccharide from Artocarpus heterophyllus Lam.（jackfruit） pulp modulates gut microbiota composition and improves short-chain fatty acids production[J]. Food Chem，2021，364:130434. DOI：10.1016/j.foodchem.2021.130434.
[59]	PANG B，ZHAO L H，ZHOU Q，et al. Application of berberine on treating type 2 diabetes mellitus[J]. Int J Endocrinol，2015，2015:905749. DOI：10.1155/2015/905749.
[60]	CUI H X，ZHANG L S，LUO Y，et al. A purified anthraquinone-glycoside preparation from rhubarb ameliorates type 2 diabetes mellitus by modulating the gut microbiota and reducing inflammation[J]. Front Microbiol，2019，10:1423. DOI：10.3389/fmicb.2019.01423.
[61]	XU X，GAO Z，YANG F，et al. Antidiabetic effects of Gegen Qinlian decoction via the gut microbiota are attributable to its key ingredient berberine[J]. Genomics Proteomics Bioinformatics，2020，18(6):721-736. DOI：10.1016/j.gpb.2019.09.007.
[62]	XIAO S，LIU C，CHEN M，et al. Scutellariae Radix and coptidis rhizoma ameliorate glycolipid metabolism of type 2 diabetic rats by modulating gut microbiota and its metabolites[J]. Appl Microbiol Biotechnol，2020，104(1):303-317. DOI：10.1007/s00253-019-10174-w.
[63]	TONG X L，XU J，LIAN F M，et al. Structural alteration of gut microbiota during the amelioration of human type 2 diabetes with hyperlipidemia by metformin and a traditional Chinese herbal formula：a multicenter，randomized，open label clinical trial[J]. mBio，2018，9(3):e2392-2317. DOI：10.1128/mBio.02392-17.
[64]	CHEN M Y，LIAO Z Q，LU B Y，et al. Huang-Lian-Jie-du-decoction ameliorates hyperglycemia and insulin resistant in association with gut microbiota modulation[J]. Front Microbiol，2018，9:2380. DOI：10.3389/fmicb.2018.02380.
[65]	WEI X Y，TAO J H，XIAO S W，et al. Xiexin Tang improves the symptom of type 2 diabetic rats by modulation of the gut microbiota[J]. Sci Rep，2018，8(1):3685. DOI：10.1038/s41598-018-22094-2.
[66]	CAO Y，YAO G W，SHENG Y Y，et al. JinQi Jiangtang tablet regulates gut microbiota and improve insulin sensitivity in type 2 diabetes mice[J]. J Diabetes Res，2019，2019:1872134. DOI：10.1155/2019/1872134.
[67]	LIU Y，WANG Y，NI Y Q，et al. Gut microbiome fermentation determines the efficacy of exercise for diabetes prevention[J]. Cell Metab，2020，31(1):77-91.e5. DOI：10.1016/j.cmet.2019.11.001.
[68]	LE CHATELIER E，NIELSEN T，QIN J J，et al. Richness of human gut microbiome correlates with metabolic markers[J]. Nature，2013，500(7464):541-546. DOI：10.1038/nature12506.
[69]	STANISLAWSKI M A，DABELEA D，LANGE L A，et al. Gut microbiota phenotypes of obesity[J]. NPJ Biofilms Microbiomes，2019，5(1):18. DOI：10.1038/s41522-019-0091-8.
[70]	MUELLER N T，DIFFERDING M K，ZHANG M，et al. Metformin affects gut microbiome composition and function and circulating short-chain fatty acids：a randomized trial[J]. Diabetes Care，2021，44(7):1462-1471. DOI：10.2337/dc20-2257.
[71]	HENNING S M，YANG J P，HSU M，et al. Decaffeinated green and black tea polyphenols decrease weight gain and alter microbiome populations and function in diet-induced obese mice[J]. Eur J Nutr，2018，57(8):2759-2769. DOI：10.1007/s00394-017-1542-8.
[72]	SANG T T，GUO C J，GUO D D，et al. Suppression of obesity and inflammation by polysaccharide from sporoderm-broken spore of Ganoderma lucidum via gut microbiota regulation[J]. Carbohydr Polym，2021，256:117594. DOI：10.1016/j.carbpol.2020.117594.
[73]	WANG K，BAO L，ZHOU N，et al. Structural modification of natural product ganomycin I leading to discovery of a α-glucosidase and HMG-CoA reductase dual inhibitor improving obesity and metabolic dysfunction in vivo[J]. J Med Chem，2018，61(8):3609-3625. DOI：10.1021/acs.jmedchem.8b00107.
[74]	WANG L，ZENG B H，LIU Z W，et al. Green tea polyphenols modulate colonic microbiota diversity and lipid metabolism in high-fat diet treated HFA mice[J]. J Food Sci，2018，83(3):864-873. DOI：10.1111/1750-3841.14058.
[75]	DING Y N，SONG Z H，LI H，et al. Honokiol ameliorates high-fat-diet-induced obesity of different sexes of mice by modulating the composition of the gut microbiota[J]. Front Immunol，2019，10:2800. DOI：10.3389/fimmu.2019.02800.
[76]	LU Y Y，FAN C N，LI P，et al. Short chain fatty acids prevent high-fat-diet-induced obesity in mice by regulating G protein-coupled receptors and gut microbiota[J]. Sci Rep，2016，6:37589. DOI：10.1038/srep37589.
[77]	ZHANG S M，ZHAO J W，XIE F，et al. Dietary fiber-derived short-chain fatty acids：a potential therapeutic target to alleviate obesity-related nonalcoholic fatty liver disease[J]. Obes Rev，2021，22(11):e13316. DOI：10.1111/obr.13316.
[78]	HONG Y，SHENG L L，ZHONG J，et al. Desulfovibrio vulgaris，a potent acetic acid-producing bacterium，attenuates nonalcoholic fatty liver disease in mice[J]. Gut Microbes，2021，13(1):1-20. DOI：10.1080/19490976.2021.1930874.
[79]	QIAO S S，BAO L，WANG K，et al. Activation of a specific gut Bacteroides-folate-liver axis benefits for the alleviation of nonalcoholic hepatic steatosis[J]. Cell Rep，2020，32(6):108005. DOI：10.1016/j.celrep.2020.108005.